NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Flamingo Therapeutics

Flamingo Therapeutics

Private
LeuvenHealthcare & Life Scienceshttps://flamingotx.com

Last Round

Grant

Jun 15, 2023

Total Funding Raised

$1.85M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Flamingo Therapeutics is a biotechnology company that develops RNA-targeted therapies for oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antisense oligonucleotideASORNA-targeted therapyoncologylncRNAlong non-coding RNAtranscription factordrug discoverybiotechclinical-stage biotechRNA therapeuticsundruggable targetsbiopharmaclinical trialsRNA medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Flamingo Therapeutics Comparables

Compare Flamingo Therapeutics with similar companies based on industry and business-model similarity.

Flamingo Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Amaroq Therapeutics
87%
HAYA Therapeutics
81%
TransCode Therapeutics, Inc.
77%

Flamingo Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 15, 2023
Corporate FundingMar 2, 2023
VC RoundJul 1, 2021

Flamingo Therapeutics Investors

Notable investors and investment history

Flamingo Therapeutics investors
InvestorRounds
University of MichiganSeries A
KU LeuvenSeries A
VLAIOGrant
PMVSeries A, VC Round, Corporate Funding
Ghent UniversitySeries A
VIBSeries A
Kurma PartnersSeries A, VC Round, Corporate Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased from 0 to 6, representing 120% of headcount.

  • Jun 1, 2025

    Monthly visitors grew 46% MoM, from 751 to 1.1K.

Flamingo Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Flamingo Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Flamingo Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLeuven
Employee Range5
Year Founded2020
Last FundingJun 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.